<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Permaesih, D.</title>
    <link>http://repub.eur.nl/res/aut/1030/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Integration of vitamin A supplementation with the expanded program on immunization does not affect seroconversion to oral poliovirus vaccine in infants. (Article)</title>
      <link>http://repub.eur.nl/res/pub/3703/</link>
      <pubDate>1999-01-01T00:00:00Z</pubDate>
      <description>Childhood immunization programs may provide
infrastructure for delivering vitamin A supplements to
infants in developing countries. The effect of giving vitamin
A, an immune enhancer, on antibody responses to trivalent
oral poliovirus vaccine (TOPV) is unknown. A randomized,
double-blind, placebo-controlled clinical trial was conducted
to determine the effect of giving vitamin A simultaneously
with TOPV on antibody responses to poliovirus.
Infants (n 5 467) received oral vitamin A, 15 mg retinol
equivalent (RE), 7.5 mg RE or placebo with TOPV at 6, 10
and 14 wk of age. Antibody responses to poliovirus types 1,
2 and 3 were measured by a microvirus neutralization assay
at enrollment and at 9 mo of age. Seroconversion rates to
poliovirus types 1, 2 and 3 ranged from 98 to 100% in the
three treatment groups, and there were no differences in
mean antibody titers to poliovirus types 1, 2 and 3 among
treatment groups. This study demonstrates that oral vitamin
A does not affect antibody responses to poliovirus
vaccine when integrated with the Expanded Program on
Immunization.</description>
    </item>
  </channel>
</rss>